CliffBio
biologic

Skyrizi

risankizumab-rzaa

Loss of exclusivityMarch 2035projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameSkyrizi
Active ingredientrisankizumab-rzaa
Strength90MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2023
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Skyrizi patent cliff — loss of exclusivity March 2035 | CliffBio